Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.
Publication
, Journal Article
Boxerman, JL; Schmainda, KM; Zhang, Z; Barboriak, DP
Published in: Neuro Oncol
November 2015
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Neuro Oncol
DOI
EISSN
1523-5866
Publication Date
November 2015
Volume
17
Issue
11
Start / End Page
1538 / 1539
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Male
- Magnetic Resonance Imaging
- Humans
- Glioblastoma
- Female
- Cerebral Cortex
- Brain Neoplasms
- Bevacizumab
- Angiogenesis Inhibitors
Citation
APA
Chicago
ICMJE
MLA
NLM
Boxerman, J. L., Schmainda, K. M., Zhang, Z., & Barboriak, D. P. (2015). Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. Neuro Oncol, 17(11), 1538–1539. https://doi.org/10.1093/neuonc/nov163
Boxerman, Jerrold L., Kathleen M. Schmainda, Zheng Zhang, and Daniel P. Barboriak. “Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.” Neuro Oncol 17, no. 11 (November 2015): 1538–39. https://doi.org/10.1093/neuonc/nov163.
Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. Neuro Oncol. 2015 Nov;17(11):1538–9.
Boxerman, Jerrold L., et al. “Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.” Neuro Oncol, vol. 17, no. 11, Nov. 2015, pp. 1538–39. Pubmed, doi:10.1093/neuonc/nov163.
Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. Neuro Oncol. 2015 Nov;17(11):1538–1539.
Published In
Neuro Oncol
DOI
EISSN
1523-5866
Publication Date
November 2015
Volume
17
Issue
11
Start / End Page
1538 / 1539
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Male
- Magnetic Resonance Imaging
- Humans
- Glioblastoma
- Female
- Cerebral Cortex
- Brain Neoplasms
- Bevacizumab
- Angiogenesis Inhibitors